Clinical Experience with Biphasic Insulin Aspart 30 Treatment in Patients with Type 2 Diabetes Poorly Controlled on Oral Antidiabetic Drugs: The Turkish PRESENT Study

Turkish Journal of Endocrinology and Metabolism

关键词: Biphasic insulin aspart;    oral antidiabetic drugs;    type 2 diabetes mellitus;    insulin analogue;    combination therapy;    clinical experience;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objective: PRESENT is the largest, completed, six-month, multi-national, open-labelled, uncontrolled, observational study of the efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) treatment in clinical practice. We present results from Turkish patients poorly controlled on oral antidiabetic treatment (OADs).Material and Methods: Only data from type 2 diabetes mellitus patients consistently prescribed BIAsp 30+OADs (n=270) or BIAsp 30 only (n=573) are presented.Result: At six months, mean HbA1c was reduced from baseline in the BIAsp 30+OADs (-2.35±1.82%) and BIAsp 30-only groups (-2.05±1.85%) (p<0.001). More patients achieved HbA1c < 7% in the BIAsp 30+OADs (33.8%) and BIAsp 30-only groups (24.6%), compared with baseline. Mean FPG and PPPG were reduced in the BIAsp 30+OADs (-85.4±72.4mg/dl; -106.8±80.2mg/dl) and BIAsp 30-only groups (-125.6±83.6 mg/dl; -153.3±87.6mg/dl), respectively (p<0.001). The majority of the hypoglycaemic episodes reported were minor and diurnal. Fifteen non-serious adverse drug reactions (ADRs) were reported in the BIAsp 30+OADs group.Conclusions: Treatment with BIAsp 30 alone or in combination with OADs effectively and safely improved glycaemic control with no major and few minor hypoglycaemic episodes among patients inadequately controlled on OADs. Turk Jem 2008; 12: 4-9

【 授权许可】

Unknown